AbbVie (ABBV) Total Current Liabilities (2012 - 2026)

AbbVie (ABBV) has 15 years of Total Current Liabilities data on file, last reported at $42.1 billion in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $42.1 billion, up 15.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.1 billion (up 15.65% YoY), and the FY2025 annual result was $43.3 billion, up 11.72% from the prior year.
• Total Current Liabilities retreated to $42.1 billion in Q1 2026 per ABBV's latest filing, from $43.3 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $43.3 billion in Q4 2025 and troughed at $27.6 billion in Q1 2023.
• A 5-year average of $36.9 billion and a median of $37.8 billion in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities retreated 16.07% in 2022, then jumped 50.5% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $29.5 billion in 2022, then increased by 28.11% to $37.8 billion in 2023, then grew by 2.4% to $38.7 billion in 2024, then grew by 11.72% to $43.3 billion in 2025, then retreated by 2.75% to $42.1 billion in 2026.
• Business Quant data shows ABBV's Total Current Liabilities at $42.1 billion in Q1 2026, $43.3 billion in Q4 2025, and $39.4 billion in Q3 2025.